Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors Journal Article
| Authors: | Mamoor, M.; Postow, M. A.; Lavery, J. A.; Baxi, S. S.; Khan, N.; Mao, J. J.; Rogak, L. J.; Sidlow, R.; Thom, B.; Wolchok, J. A.; Korenstein, D. |
| Article Title: | Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors |
| Abstract: | Background Immune checkpoint inhibitors (CIs) have revolutionized treatment of advanced melanoma, leading to an emerging population of long-term survivors. Survivors' quality of life (QOL) and symptom burden are poorly understood. We set out to evaluate symptom burden and QOL in patients with advanced melanoma alive more than 1 year after initiating CI therapy. Methods Cross-sectional surveys, accompanied by chart review of patients with advanced melanoma treated with CIs at Memorial Sloan Kettering Cancer Center, completed therapy, and were alive >1 year after treatment initiation. Surveys were administered between February and August 2018. Surveys included: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, EuroQOL, items from Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events and Fatigue Severity Scale. Results We included 90 patients. The most common CI regimens were ipilimumab plus nivolumab (53%) and pembrolizumab (41%); most patients (71%) were not treated in clinical trials. Median time from CI therapy initiation was 40 months and from last dose was 28 months. Fatigue was reported by 28%, with higher fatigue scores in women than men; 12% reported difficulty sleeping. Aching joints (17%) and muscles (12%) were fairly common. Level of functioning was generally high. Overall QOL was excellent though 40% reported â € some or moderate' problems with anxiety/depression and 31% with pain/discomfort. Conclusions After CI therapy, long-surviving advanced melanoma patients commonly report fatigue but otherwise have moderate symptom burden and good QOL. Ensuring appropriate symptom management will optimize clinical outcomes for these patients. © © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
| Keywords: | adult; cancer chemotherapy; controlled study; treatment outcome; aged; clinical trial; fatigue; paresthesia; hepatitis; advanced cancer; treatment duration; prospective study; ipilimumab; melanoma; quality of life; heart disease; kidney disease; lung disease; myalgia; cohort analysis; oncology; cancer survivor; arthralgia; rash; questionnaire; patient care; depression; immunology; colitis; cross-sectional study; anxiety; hypothyroidism; visual impairment; musculoskeletal disease; endocrine disease; self care; hypophysitis; nivolumab; charlson comorbidity index; human; male; female; priority journal; article; checkpoint kinase inhibitor; pembrolizumab; european organization for research and treatment of cancer quality of life questionnaire core 30; european quality of life 5 dimensions questionnaire; comprehensive score for financial toxicity; fatigue severity scale; patient reported outcomes version of the common terminology criteria for adverse events |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 8 |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2020-03-08 |
| Start Page: | e000260 |
| Language: | English |
| DOI: | 10.1136/jitc-2019-000260 |
| PUBMED: | 32152222 |
| PROVIDER: | scopus |
| PMCID: | PMC7061889 |
| DOI/URL: | |
| Notes: | Article -- Jedd A. Wolchok's middle initial is incorrect on the original publication -- Erratum issued, see DOI: 10.1136/jitc-2019-000260corr1 -- Export Date: 1 April 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work